Who are RDD to Palynziq's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Panzytrat 25.000 FIP-E units of Lipase, Fabrazyme (agalsidase beta), Naglazyme®, creon 35.000 Ph.U (R), Cerezyme® / Imiglucerase, Elelyso.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rdd-to-palynziq.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

RDD to Palynziq — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RDD to Palynziq (RDD to Palynziq) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Metabolic/Genetic disorder.

marketed Enzyme replacement therapy Phenylalanine ammonia-lyase (PAL) Metabolic/Genetic disorder Small molecule Live · refreshed every 30 min

Target snapshot

RDD to Palynziq (RDD to Palynziq) — BioMarin Pharmaceutical. Palynziq is a recombinant phenylalanine ammonia-lyase (PAL) enzyme that breaks down phenylalanine, reducing blood phenylalanine levels in patients with phenylketonuria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RDD to Palynziq TARGET	RDD to Palynziq	BioMarin Pharmaceutical	marketed	Enzyme replacement therapy	Phenylalanine ammonia-lyase (PAL)
Panzytrat 25.000 FIP-E units of Lipase	Panzytrat 25.000 FIP-E units of Lipase	Foundation for Liver Research	marketed	Pancreatic enzyme replacement therapy	Triglycerides and dietary lipids
Fabrazyme (agalsidase beta)	Fabrazyme (agalsidase beta)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy (ERT); recombinant enzyme	α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)
Naglazyme®	Naglazyme®	Masonic Cancer Center, University of Minnesota	marketed	Enzyme replacement therapy	Arylsulfatase B (ARSB)
creon 35.000 Ph.U (R)	creon 35.000 Ph.U (R)	Hospital Clinico Universitario de Santiago	marketed	Pancreatic enzyme replacement therapy
Cerezyme® / Imiglucerase	Cerezyme® / Imiglucerase	Sanofi	marketed	Enzyme replacement therapy	Glucocerebrosidase (β-glucosidase)
Elelyso	Taliglucerase Alfa	Pfizer Inc.	marketed	Enzyme replacement therapy	Glucocerebroside (substrate); mannose receptors on cell surface

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RDD to Palynziq — Competitive Intelligence Brief. https://druglandscape.com/ci/rdd-to-palynziq. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab